Literature DB >> 14732925

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

Patricia A Mote1, Jennifer A Leary, Kelly A Avery, Kerstin Sandelin, Georgia Chenevix-Trench, Judy A Kirk, Christine L Clarke.   

Abstract

The breast cancer susceptibility genes BRCA1 and BRCA2 are responsible for a large proportion of familial breast and ovarian cancer, yet little is known of how disruptions in the functions of the proteins these genes encode increased cancer risk preferentially in hormone-dependent tissue. There is no information on whether a germ-line mutation in BRCA1 or BRCA2 causes disruptions in hormone-signaling pathways in the normal breast. In this study markers of hormone responsiveness were measured in prophylactically removed normal breast tissue (n = 31) in women bearing a germ-line pathogenic mutation in one of the BRCA genes. The estrogen receptor (ER) and proteins associated with ER action in hormone-sensitive tissues, namely, PS2 and the progesterone receptor (PR), were detected immunohistochemically. ER expression was not different in BRCA mutation carriers than in noncarriers, but there was a reduction in PS2 expression. PR expression was also reduced, and there was a striking lack of expression of the PRB isoform, which resulted in cases with PRA-only expression in BRCA1 and BRCA2 mutation carriers. The alterations in PS2 and PR expression were similar in the BRCA1 and BRCA2 carriers, demonstrating that although these proteins are structurally and functionally distinct, there is overlap in their interaction with hormone-signaling pathways. This study provides evidence for altered cell function arising from loss of function of one BRCA allele in the normal breast, leading to PS2 loss, preferential PRB loss, and expression of PRA alone. In breast cancer development, PRA overexpression becomes evident in premalignant lesions and is associated with features of poor prognosis in invasive disease and altered cell function in vitro. The results of this study suggest that heterozygosity for a germ-line mutation in BRCA1 or BRCA2 results in development of PRA predominance. This is likely to lead to changes in progesterone signaling in hormone-dependent tissues, which may be a factor in the increased risk of cancer in these tissues in women with germ-line BRCA1 or BRCA2 mutations. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732925     DOI: 10.1002/gcc.10321

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  29 in total

Review 1.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

2.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Authors:  Hiroyuki Konishi; Morassa Mohseni; Akina Tamaki; Joseph P Garay; Sarah Croessmann; Sivasundaram Karnan; Akinobu Ota; Hong Yuen Wong; Yuko Konishi; Bedri Karakas; Khola Tahir; Abde M Abukhdeir; John P Gustin; Justin Cidado; Grace M Wang; David Cosgrove; Rory Cochran; Danijela Jelovac; Michaela J Higgins; Sabrina Arena; Lauren Hawkins; Josh Lauring; Amy L Gross; Christopher M Heaphy; Yositaka Hosokawa; Edward Gabrielson; Alan K Meeker; Kala Visvanathan; Pedram Argani; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

3.  BRCA1 Attenuates Progesterone Effects on Proliferation and NFκB Activation in Normal Human Mammary Epithelial Cells.

Authors:  H N Hilton; L J Patterson McDonald; N Santucci; F R van der Bent; A Silvestri; J D Graham; C L Clarke
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-05-18       Impact factor: 2.673

4.  Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.

Authors:  Michela Palleschi; Maria Laura Iaia; Chiara Casadei
Journal:  Breast Cancer Res Treat       Date:  2020-11-10       Impact factor: 4.872

Review 5.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

6.  Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.

Authors:  Alana A Lewin; Sungheon Gene Kim; James S Babb; Amy N Melsaether; Jason McKellop; Melanie Moccaldi; Ana Paula Klautau Leite; Linda Moy
Journal:  Acad Radiol       Date:  2016-01-07       Impact factor: 3.173

7.  Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.

Authors:  Nathalie Esber; Clément Cherbonnier; Michèle Resche-Rigon; Abdallah Hamze; Mouad Alami; Jérôme Fagart; Hugues Loosfelt; Marc Lombès; Nathalie Chabbert-Buffet
Journal:  Horm Cancer       Date:  2016-03-03       Impact factor: 3.869

Review 8.  Progesterone receptor isoform functions in normal breast development and breast cancer.

Authors:  Anastasia Kariagina; Mark D Aupperlee; Sandra Z Haslam
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2008       Impact factor: 1.807

9.  CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Authors:  Shauna N Vasilatos; Gloria Broadwater; William T Barry; Joseph C Baker; Siya Lem; Eric C Dietze; Gregory R Bean; Andrew D Bryson; Patrick G Pilie; Vanessa Goldenberg; David Skaar; Carolyn Paisie; Alejandro Torres-Hernandez; Tracey L Grant; Lee G Wilke; Catherine Ibarra-Drendall; Julie H Ostrander; Nicholas C D'Amato; Carola Zalles; Randy Jirtle; Valerie M Weaver; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

Review 10.  BRCA1, hormone, and tissue-specific tumor suppression.

Authors:  Yanfen Hu
Journal:  Int J Biol Sci       Date:  2008-12-13       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.